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Abstract
Background: In asthma, higher chymase positive mast cell (MC-C) numbers are associated with
less airway obstruction. In COPD, the distribution of MC-C and tryptase positive mast cells (MC-
T) in central and peripheral airways, and their relation with lung function, is unknown. We
compared MC-T and MC-C distributions in COPD and controls without airflow limitation, and
determined their relation with lung function.
Methods: Lung tissue sections from 19 COPD patients (median [interquartile range] FEV1%
predicted 56 [23–75]) and 10 controls were stained for tryptase and chymase. Numbers of MC-T
and MC-C were determined in different regions of central and peripheral airways and percentage
of degranulation was determined.
Results: COPD patients had lower MC-T numbers in the subepithelial area of central airways than
controls. In COPD, MC-T numbers in the airway wall and more specifically in the epithelium and
subepithelial area of peripheral airways correlated positively with FEV1/VC (Spearman's rho (rs)
0.47, p = 0.05 and rs 0.48, p = 0.05, respectively); MC-C numbers in airway smooth muscle of
peripheral airways correlated positively with FEV1% predicted (rs 0.57, p = 0.02). Both in COPD
patients and controls the percentage of degranulated MC-T and MC-C mast cells was higher in
peripheral than in central airways (all p < 0.05), but this was not different between the groups.
Conclusion: More MC-T and MC-C in peripheral airways correlate with better lung function in
COPD patients. It is yet to determine whether this reflects a protective association of mast cells
with COPD pathogenesis, or that other explanations are to be considered.
Introduction
Chronic obstructive pulmonary disease (COPD) is charac-
terized by inflammation in both central and peripheral
airways [1], which is dominated by neutrophils, macro-
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phages, T lymphocytes (mainly CD8+ cells), and B lym-
phocytes [2-4]. In addition, some [5,6] but not all studies
[7,8], have demonstrated higher numbers of mast cells in
patients with COPD than in controls without airflow lim-
itation. Theoretically, mast cells could play a role in the
pathogenesis of COPD [9] by inducing collagen produc-
tion [10] fibroblast proliferation [11,12], and release of
various mediators, including the potent proteases tryptase
and chymase. Tryptase, a mast cell specific protease, is
present in all human mast cells, whereas chymase is
present in a subset of mast cells.
Balzar and co-workers recently evaluated the number of
chymase and tryptase positive mast cells in central and
peripheral airways of patients with severe asthma [13].
They demonstrated that higher numbers of chymase pos-
itive mast cells in peripheral airways are associated with
less severe airflow limitation. Therefore, they suggested
that mast cells are protective for enhanced airway obstruc-
tion in patients with asthma.
To our knowledge, the distribution of chymase and tryp-
tase positive mast cells in central and peripheral airways,
and their relation with lung function has not been inves-
tigated previously in patients with COPD. This study did
so and compared this distribution with results in controls
without airflow limitation.
Methods
Subjects and tissue collection
Tissue samples were collected from 29 individuals: 19
with COPD and 10 controls without airflow limitation
(Table 1). COPD patients had no chronic bronchitis or
α1-antitrypsin deficiency (10 males, median [interquartile
range] age 62 [54–72], pack-years 31 [27–40]) and they
were former- or current smokers (14 and 5 patients,
respectively). They had mild to very severe COPD accord-
ing to the Global Initiative on Lung Disease (GOLD) cri-
teria (stage I, II, III, IV in 3, 8, 1, and 7 patients,
respectively) [14]. Forced expiratory volume in one sec-
ond (FEV1) as percentage of predicted (% pred) was 56
[23–75], with an FEV1/vital capacity (VC) ratio of 50%
[30–59]. Thirteen out of 19 patients with COPD were
treated with oral or inhaled corticosteroids or their com-
bination. Controls without airflow limitation and with-
out corticosteroid use (8 males, age 56 [47–70], pack years
30 [25–50]) were former (n = 5) or current (n = 4) smok-
ers; smoking status of 1 control was unknown. Median
[range] FEV1% pred of the control group was 103 [90–
106], and FEV1/VC ratio 72% [72–75]. Lung function data
were missing from one control, a 43-year-old male organ
donor, from whom we obtained lung tissue that had not
been used for transplantation because of logistic (unilat-
eral transplantation) reasons. An experienced pulmonary
pathologist (WT) found no signs of COPD or other signif-
icant pathology in lung tissue.
Lung tissue samples from GOLD stage IV COPD patients
were obtained from tissue remaining after standard
pathology protocols in case of lung transplant procedures.
The other tissue samples were obtained from subjects
undergoing partial resection, (bi)lobectomy, or pneu-
monectomy for pulmonary carcinoma or metastasis.
None of the patients had received chemotherapy. Lung
tissue was taken as distant as possible from the tumor, or
from non-involved lobes. The study protocol was consist-
ent with national ethical and professional guidelines
("Code of Conduct; Dutch Federation of Biomedical Sci-
entific Societies"; http://www.federa.org).
Tissue processing/immunohistochemistry
Immunohistochemistry was performed on 3 μm formalin
fixed, paraffin embedded lung tissue sections. Consecu-
tive tissue sections were stained for tryptase (AA1, DAKO,
Glostrup, Denmark) and chymase (CC1, Abcam, Cam-
bridge, UK) using an immuno-alkaline phosphatase
method with goat-anti-mouse immunoglobulin conju-
gated to alkaline phosphatase as a second step and Fast
Red/Napthol AS-Mx as a chromogen providing a bright
red reaction product. Double staining was performed to
delineate the different compartments. After chymase or
tryptase staining, slides were incubated with a mixture of
mouse monoclonal antibodies detecting anti-alpha-
smooth-muscle actin (Progen, Heidelberg, Germany;
clone ASM-1) and pan-keratin (AE1-AE3, Boehringer
Mannheim, Mannheim, Germany). As a detection step,
slides were incubated with rabbit anti-mouse immu-
noglobulin conjugated to peroxidase. 3'3'di-amino-ben-
zidin together with H2O2  was used as a chromogen,
providing a gold-brown reaction product. This double
staining procedure with subsequent incubation steps
Table 1: Characteristics of COPD patients and controls
Controls COPD
N1 0 1 9
Male/female 8/2 10/9
Current smoker (y/n/unknown) 4/5/1* 5/14/0
Age (median IQR) 56 (47–70) 62 (54–72)
Packyears (median (range)) 30 (25–50) * 31 (27–40)
ICS (y/n/unknown) 0/9/1* 8/11/0
OCS (y/n/unknown) 0/9/1* 7/12/0
ICS and/or OCS (y/n/unknown) 0/9/1* 13/6/0
B2 agonist (y/n/unknown) 0/9/1* 10/9/0
Anticholinergics (y/n/unknown) 0/9/1* 10/9/0
COPD Severity Stage (GOLD 1/2/3/4) - 3/8/1/7
FEV1 (% predicted) 103 (92–107)** 56 (23–75)
FEV1/IVC (%) 72 (72–75)** 50 (30–59)
Data are presented as median (IQR)
* n = 9; 1 subject (anonymous donor) with some missing data; ** n = 
8, 2 subjects (incl. donor) with missing lung function dataRespiratory Research 2008, 9:64 http://respiratory-research.com/content/9/1/64
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allowed easy identification of mast cells with clear demar-
cation of smooth muscle area and delineation of bron-
chial epithelium, as well as outer limit of adventitia by
(mainly type 2) alveolar epithelial cells (see figure 1 for
illustration). Appropriate isotype matched control sera
were used for negative controls.
Definition of lung regions and morphometric analysis
We examined 1 central airway and, depending on the
availability, 1 to 5 peripheral airways from each subject.
Central airways were defined as cartilaginous airways,
maximum from the third generation. Three central airway
regions were analyzed separately: 1) epithelium; 2) subep-
ithelial area (area between the bronchial epithelium and
smooth muscle layer); and 3) airway smooth muscle.
Peripheral airways were defined as airways with a circum-
ferential size of maximally 6 mm, and a variation of max-
imal versus minimal diameter ≤ two-fold. Four peripheral
airway regions were analyzed separately: 1) epithelium; 2)
subepithelial area; 3) airway smooth muscle; and 4)
adventitia (area outside smooth muscle to the connection
points of the surrounding parenchyma).
All areas were measured using the Leica QuantiMed mor-
phometric system (Leica Microsystems, Lübeck, Ger-
many) and chymase and tryptase positive, nucleated cells
were counted manually within each area and in addition
related to all these areas together.
The percentage of degranulation was determined for all
MC-C and MC-T mast cells, using the method of Carroll et
al [15]. In short, at a high power (x400) magnification,
positively-stained nucleated mast cells were classified as
intact if they were dense, compact, had unbroken cyto-
plasmic boundaries and did not have any surrounding
positively stained granules. All other nucleated tryptase or
chymase positive cells were classified as degranulated.
Degranulated cells were expressed as a percentage of the
total number of nucleated MC-T or MC-C-positive cells
for the whole small or large airway section.
A random selection of 10% of all tryptase sections was
recounted to determine the intra-class correlation coeffi-
cient (ICC), reflecting level of agreement for repeat counts
by the same observer. The same was done by two inde-
pendent observers to determine inter-observer agreement.
Statistical analysis
Means and standard deviations or medians with inter-
quartile ranges (IQR) of variables were calculated. Num-
bers of chymase and tryptase positive mast cells were
expressed per mm length of basement membrane (epithe-
lium) or mm2 area (subepithelial area, airway smooth
muscle, and adventitia). In case two or more peripheral
airways from one subject were examined, mean cell con-
centration of all peripheral airways from this subject was
used for statistical analysis. Differences between groups
were analyzed using Chi-Square or Mann-Whitney U-
tests, paired analyses within groups using Wilcoxon-rank-
sum-tests, and correlations between cell concentrations
and lung function using Spearman's rank correlation coef-
ficient (rs). SPSS 12.0 (SPSS Inc., Chicago, IL) software
was used for statistical analysis. A p-value of 0.05 or less
was considered significant.
1a. (left) Double immunostaining: tryptase positive mast cells (bright red) in a small airway in a tissue sample from a patient  with moderate COPD (GOLD stage 2); bronchial and alveolar type 2 epithelial cells and smooth muscle stain golden brown,  magnification × 100 Figure 1
1a. (left) Double immunostaining: tryptase positive mast cells (bright red) in a small airway in a tissue sample 
from a patient with moderate COPD (GOLD stage 2); bronchial and alveolar type 2 epithelial cells and 
smooth muscle stain golden brown, magnification × 100; 1b. (right) larger magnification (× 200).Respiratory Research 2008, 9:64 http://respiratory-research.com/content/9/1/64
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Results
Patient characteristics (Table 1)
Patients with COPD had significantly lower FEV1  (%
pred) and FEV1/VC values than controls without airflow
limitation (both p < 0.001). Gender, smoking status, and
pack-years smoking were similar in the two groups (p >
0.05).
Morphometric analysis
Central airways
Median [IQR] length of epithelium analyzed in the total
study population was 7.5 mm [7.3–7.6], median tissue
area 0.7 mm2 [0.5–1.2] for the subepithelial area, and 0.6
mm2 [0.4–0.9] for airway smooth muscle.
Peripheral airways
The length of epithelium per tissue section analyzed in the
total study population was 2.3 mm [2.0–2.8] per periph-
eral airway. Median tissue area analyzed was 0.02 mm2
[0.02–0.04] for the subepithelial area, 0.02 mm2 [0.01–
0.03] for airway smooth muscle, and 0.1 mm2 [0.1–0.2]
for the adventitia. Comparable tissue areas were analyzed
in the two groups (p > 0.05).
Distribution of mast cells in central and peripheral airways 
in COPD and controls (Table 2, Figure 1))
Tryptase positive mast cells (MC-T)
In central airways, the concentration of MC-T was highest
in the subepithelial area in both groups (Table 2a). In
peripheral airways (Figure 1), the concentration of MC-T
was highest in the adventitia followed by the subepithelial
area in both groups.
The concentration of MC-T was significantly lower in the
subepithelial area of central airways from patients with
COPD than from controls (53.7/mm2 [25.7–120.8] ver-
sus 108.8/mm2  [83.9–190.2], respectively, p = 0.04).
Concentrations of MC-T in any of the other regions of cen-
tral and peripheral airways were similar in both groups (p
> 0.05).
Table 2: 
a. The concentration of tryptase positive mast cells (MC-T) per region for patients with COPD and controls
Controls
(n = 10)
COPD
(n = 19)
Central airways
Epithelium (cells/mm) 0.07 [0.0–0.9] 0.0 [0.0–0.1]
Subepithelial area (cells/mm2) 108.8 [83.9–190.2] 53.7 [25.7–120.8]¶
Airway smooth muscle (cells/mm2) 32.5 [15.8–49.9] 20.1 [10.5–33.3]
% degranulated mast cells 35.9 [21.9–51.2] 28.0 [22.4–37.4]
Peripheral airways
Epithelium (cells/mm) 0.0 [0.0–0.9] 0.0 [0.0–0.2]
Subepithelial area (cells/mm2) 247.9 [73.9–548.2] 184.6 [100.4–282.3]
Airway smooth muscle (cells/mm2) 12.6 [0.0–36.9] 18.4 [0.0–47.6]
Adventitia (cells/mm2) 279.4 [79.2–646.9] 214.9 [107.2–327.2]
% degranulated mast cells 68.6 [41.5–81.4] 67.5 [53.0–84.1]
b. The concentration of chymase positive mast cells (MC-C) per region for patients with COPD and controls
Controls
(n = 10)
COPD
(n = 19)
Central airway samples
Epithelium (cells/mm) 0.0 [0.0–0.0] 0.0 [0.0–0.3]¶¶
Subepithelial area (cells/mm2) 18.1 [8.2–28.9] 11.0 [4.5–28.3]
Airway smooth muscle (cells/mm2) 10.6 [2.7–15.2] 3.5 [0.0–6.0]
% degranulated mast cells 33.3 [25.7–52.2] 40.0 [26.8–58.3]
Peripheral airways
Epithelium (cells/mm) 0.0 [0.0–0.0] 0.0 [0.0–0.2]
Subepithelial area (cells/mm2) 19.4 [0.0–71.8] 54.5 [0.0–160.0]
Airway smooth muscle (cells/mm2) 0.0 [0.0–54.1] 0.0 [0.0–50.7]
Adventitial layer (cells/mm2) 128.0 [44.1–184.0] 68.5 [13.2–162.7]
% degranulated mast cells 66.8 [55.6–93.2] 63.9 [52.1–95.0]
Data are presented as median [interquartile range]; ¶ p = 0.035 versus controls; ¶¶p = 0.045 vs controlsRespiratory Research 2008, 9:64 http://respiratory-research.com/content/9/1/64
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MC-T numbers were significantly higher in subepithelial
area in peripheral airways than in central airways in both
COPD patients and controls (p = 0.01 and 0.03 respec-
tively) without a difference in numbers in smooth muscle.
Chymase positive mast cells (MC-C)
Concentrations of MC-C were highest in the subepithelial
area of central airways in both patients with COPD and
controls (Table 2b). In peripheral airways, the concentra-
tion of MC-C was highest in the adventitia followed by the
subepithelial area in both groups.
The concentration of MC-C was significantly higher in the
epithelium of central airways from patients with COPD
than from controls, but with very low cell numbers (0.0
[0.0–0.0]/mm2 versus 0.0/mm2 [0.0–0.3], respectively, p
= 0.05). Concentrations of MC-C in any other of the
regions of both central and peripheral airways were simi-
lar in both groups.
MC-C numbers were significantly higher in both subepi-
thelial area and smooth muscle area of peripheral airways
than in central airways in COPD patients (p = 0.03 and
0.05 respectively), but not in controls (p = 0.88 and 0.67
respectively).
The percentage of degranulated mast cells was higher in
peripheral than in central airways for MC-T as well as MC-
C (both p < .001), but was not significantly different
between COPD and controls.
Exclusion of 2 control subjects with missing lung function
data did not affect any of the results. A subgroup analysis
excluding all COPD patients treated with corticosteroids
provided similar results as presented above. The inter-
group difference in subepithelial MC-T in central airways
was reduced to a trend (p = 0.09), probably due to loss of
power.
The ICC for the intra-observer variability was 0.96; the
inter-observer variability for two independent observers
resulted in an ICC of 0.98. This reflects excellent levels of
agreement for repeat counts by either the same observer or
two independent observers.
Relation between mast cells and lung function in COPD 
patients
Tryptase positive mast cells
Higher numbers of MC-T in the epithelium and in the
subepithelial area of peripheral airways correlated signifi-
cantly with higher values of FEV1/VC (rs 0.47, p = 0.05 and
rs 0.48, p = 0.05, respectively; figure 2a and 2b), but not
with FEV1% pred (rs 0.29, p = 0.25 and rs 0.34, p = 0.17,
respectively). Higher numbers of MC-T in the adventitia
of peripheral airways tended to correlate with higher val-
ues of FEV1/VC (rs 0.41, p = 0.09) and FEV1% pred (rs 0.43,
p = 0.08). A higher percentage of MC-T in the total airway
wall area of peripheral airways also correlated signifi-
cantly with higher values of FEV1 and FEV1/VC (rs 0.52, p
= 0.03 and rs 0.55, p = 0.02).
No significant correlations existed between the number of
MC-T in any of the other airway regions and lung function
(either expressed as FEV1% pred or FEV1/VC).
Chymase positive mast cells
Higher numbers of MC-C in the smooth airway muscle of
peripheral airways correlated significantly with higher val-
ues of FEV1% pred (rs0.57, p = 0.02; figure 3), but not with
FEV1/VC (rs 0.35, p = 0.17). Higher numbers of MC-C in
the adventitia of peripheral airways tended to correlate
positively with FEV1% pred (rs 0.43, p = 0.08).
We found no significant correlations between the number
of MC-C in any of the other airway regions and lung func-
tion (either expressed as FEV1% pred or FEV1/VC).
Discussion
In the present study, we demonstrate that the distribution
of tryptase and chymase positive mast cells in the airways
is similar in patients with COPD and controls without air-
flow limitation. In central airways, the concentration of
both tryptase and chymase positive mast cells is highest in
the subepithelial area. In peripheral airways, the concen-
tration is highest in the adventitia, followed by almost
similar high numbers in the subepithelial area. Interest-
ingly, the numbers of mast cells differed between COPD
and controls. Numbers of tryptase positive mast cells in
the subepithelial area of central airways were lower in
COPD than in controls, without other relevant significant
differences. Finally, a higher number of tryptase and chy-
mase positive mast cells in different regions and for tryp-
tase also in the total  wall area of peripheral airways is
associated with less severe airflow limitation in COPD,
relationships not observed in central airways.
Previous studies on the role of mast cells in COPD have
not investigated both central and peripheral airways nor
the relation of mast cells and their specific granule con-
tents with lung function [5,16]. We observed no differ-
ence in the number of MC-T in peripheral airways
between patients with COPD and controls. In contrast,
Grashoff et al. demonstrated higher numbers of MC-T in
the epithelium of peripheral airways, (but not in the
remainder of the airway wall) in patients with COPD than
in controls [5]. These seemingly incongruent findings may
be due to the definition of COPD and controls used in
both studies. We adhered to current guidelines [14,17]
taking both FEV1 and FEV1/VC into account, whereas
Grashoff's study, conducted before these guidelines wereRespiratory Research 2008, 9:64 http://respiratory-research.com/content/9/1/64
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introduced, selected groups solely based on FEV1. Com-
patible with our findings, no correlation between MC-T in
central airways and FEV1 was observed in another study
investigating a heterogeneous population of 29 current
smokers with and without airflow limitation [16]. The
number of MC-T in peripheral airways was not assessed in
the latter study. Interestingly, our findings are in keeping
with a recent study in severe asthma [13], where higher
numbers of MC-C in peripheral airways were associated
with less severe airflow limitation [13]. However, in con-
trast to our findings, the asthma study did not observe
such a relation for the number of MC-T and lung function.
Thus, the present study is the first to report the relation of
both tryptase and chymase positive mast cells in both cen-
tral and peripheral airways with lung function in patients
with COPD.
There are a few considerations when interpreting our
results. Some studies [16] but not all [18], have shown
higher numbers of airway mast cells in current than in ex-
or never smokers. We observed a significantly lower
number of MC-T in the subepithelial area of central air-
ways in COPD than in controls. This might have been
influenced by a higher percentage of current smokers in
the control group, yet controls and COPD had similar
smoking status. Furthermore, 13 of our 19 COPD patients
were treated with corticosteroids versus none of the con-
trols (p < 0.001). Treatment with corticosteroids can
reduce mast cell numbers in central airways of patients
with COPD [19,20]. However, as indicated in the results
section, a subgroup analysis excluding all COPD patients
treated with corticosteroids provided similar results as
presented above.
Another point which might have had an impact on our
results is that we used lung tissue obtained during surgery
for lung cancer. The relation between tumour and mast
cells has mainly been studied with respect to mast cells in
the tumour tissue and/or effects of mast cells on the
tumour [21]. In fact the only effects reported so far are
related to mast cells in the immediate environment of
tumour-cells or effects of chemotherapy on mast cell
number and function.[21] To limit effects of the tumour
on airflow limitation and inflammation, we only
included patients, who had not received chemotherapy,
with a peripherally localized tumour, and selected lung
tissue as far as possible from the tumour. Taken together,
we feel that the results we describe are valid.
The relation between the concentration of tryptase positive mast cells and lung function in patients with COPD for 2a Figure 2
The relation between the concentration of tryptase positive mast cells and lung function in patients with 
COPD. 2a. MC-T in the epithelium of peripheral airways and FEV1/VC (%). 2b. MC-T in the subepithelial area of peripheral 
airways with FEV1/VC (%). FEV1/VC = the ratio of the forced expiratory volume in one second and vital capacity; MC-T = tryp-
tase positive mast cells.Respiratory Research 2008, 9:64 http://respiratory-research.com/content/9/1/64
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How to put the present results in perspective of the under-
lying pathophysiology of COPD? The significant relation
of MC-T and MC-C with airflow limitation in COPD was
present in peripheral and not central airways, compatible
with the widely accepted notion that peripheral airways
are the major site of airflow limitation in COPD [2,22]. In
line with a previous study in severe asthmatics [13], but
yet to our surprise, a positive relation was found between
mast cell numbers and lung function. This may either
reflect a protective role of mast cells in the pathogenesis of
COPD, or in contrast, it may represent a risk factor if lower
numbers of MC-T and MC-C reflect increased degranula-
tion of mast cells, leaving them undetected in an immu-
nohistochemical approach [23]. Previous findings in
asthma showed that the proportion of degranulated mast
cells is higher in peripheral airways from patients with
asthma than in controls [15]. In the present study, using
the same protocol, we did not find a difference in degran-
ulation in central or small airways between COPD
patients and control subjects. For both groups we found
more MC-T in peripheral than in subepithelial area of the
central airways, whereas in COPD, but not in controls,
there are less MC-C in the subepithelial area and more in
the smooth muscle area in the peripheral airways than in
the central airways. Moreover, for both groups we found a
significantly higher percentage of MC-T and MC-C
degranulation in peripheral than in central airways. Both
numbers and percentage of degranulation of MC-T and
MC-C were not different for COPD patients and control
subjects. In the article and on-line supplement of Battaglia
et al. [24] a similar increase of mast cells in peripheral air-
ways has been described for ex- and current smokers, with
or without COPD. Apparently, the quite extensive pres-
ence and degranulation of mast cells in peripheral airways
does not necessarily lead to airway obstruction and may
have other physiologic effects.
We realize that there are several arguments against a pro-
tective role for mast cells in COPD, since they secrete e.g.
proteases, interleukin-8 [25] and tumour necrosis factor
(TNF). [26,27] These cytokines contribute to neutrophilic
inflammation in COPD [28-30], which is in turn associ-
ated with more severe airflow limitation [8]. Indeed mast
cells generally have detrimental effects in various inflam-
matory conditions [31-33]. However, mast cells can have
quite opposing effects in different situations, rather
dependent on their micro-environment and the mast cell
modulating factors that play a role at that particular
microlocalization [9]. Moreover, there are potential bene-
ficial effects as well. Mast cells were associated with a pro-
tective role in e.g. the development of glomerulonephritis
in mice models of renal inflammatory disease [34]. Fur-
thermore, they might protect against the detrimental
smoke effects on lung function by the ability of tryptase to
enhance epithelial cell proliferation [35], which could
improve epithelial integrity. In addition, chymase may
inhibit smooth muscle proliferation and thus the associ-
ated increased peripheral airway resistance in patients
with COPD [36]. The proteases that are produced by
mast-cells may limit the development of subepithelial
fibrosis. Finally, mast cells can also have the opposite
effect and contribute to fibroblast proliferation and colla-
gen production [10-12,37]. This might increase extracellu-
lar matrix production in the adventitia, thereby
counteracting effects of emphysematous destruction of
peribronchial attachments.
In conclusion, in our view, the strength of the current
study is that it is the first to investigate the distribution of
tryptase and chymase positive mast cells in central and
peripheral airways, and their relation with airflow limita-
tion in patients with COPD. It remains to be clarified
whether our findings reflect a beneficial or a detrimental
effect of mast cells, or even a combination of both, on
lung function in patients with COPD.
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The relation between the concentration of chymase positive  mast cells in peripheral airways smooth muscle with FEV1%  predicted in patients with COPD Figure 3
The relation between the concentration of chymase 
positive mast cells in peripheral airways smooth mus-
cle with FEV1% predicted in patients with COPD. 
FEV1 = forced expiratory volume in one second; % predicted 
= percentage of the predicted value; MC-C = chymase posi-
tive mast cells.Respiratory Research 2008, 9:64 http://respiratory-research.com/content/9/1/64
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